Rahul Mahajan

Rahul Mahajan

Auto-generated profile, based on publicly available information

Rahul Mahajan

Department of Dermatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Indian Dermatology Online Journal
Verified
Journal Article
Open access
PDF file
RMRahul Mahajan
Rahul Mahajan
ASAlok Kumar Sahoo
Alok Kumar Sahoo
The prevalence of superficial mycotic infection worldwide is 20–25% of which dermatophytes are the most common agents. Recent developments in understanding the pathophysiology of dermatophytosis have confirmed the central role of cell-mediated immunity in countering these infections. Hence, a lack of delayed hypersensitivity reaction in presence of a positive immediate hypersensitivity (IH) response to trichophytin antigen points toward the chronicity of disease. Diagnosis, though essentially clinical should be confirmed by laboratory-based investigations. Several new techniques such as polymerase chain reaction (PCR) and mass spectroscopy can help to identify the different dermatophyte strains. Management involves the use of topical antifungals in limited disease, and oral therapy is usually reserved for more extensive cases. The last few years have seen a significant rise in the incidence of chronic dermatophyte infections of skin which have proven difficult to treat. However, due to the lack of updated national or international guidelines on the management of tinea corporis, cruris, and pedis, treatment with systemic antifungals is often empirical. The present review aims to revisit this important topic and will detail the recent advances in the pathophysiology and management of tinea corporis, tinea cruris, and tinea pedia while highlighting the lack of clarity of certain management issues.

1 January 2016 in Indian Dermatology Online Journal
Verified
Journal Article
Open access
PDF file
SDSunil Dogra
Sunil Dogra
RMRahul Mahajan
Rahul Mahajan
On the basis of current evidence derived from hospital-based studies, mostly from North India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%, with a much lower prevalence in children. The peak age at onset in adults is in the third and fourth decade of life, with a slight male preponderance. It is recommended that population-based large epidemiologic studies should be undertaken in different parts of the country for estimating the correct prevalence of psoriasis in general population. Chronic plaque-type psoriasis is the most common morphologic presentation of psoriasis, accounting for more than 90% of all cases. Other morphologic variants that deserve special mention include palmoplantar psoriasis, pustular psoriasis, and recalcitrant psoriasis.For epidemiologic purposes, psoriasis can be classified into early and late onset psoriasis. Psoriasis can be classified on the basis of morphology and extent of involvement into localized and widespread disease.For the purpose of clinical trials, psoriasis may be classified as mild psoriasis, moderate psoriasis, and severe psoriasis. The literature shows that there is a significant risk of psoriatic arthritis (7–48%) in patients with plaque-type psoriasis. Hence, it is recommended to evaluate for its presence by detailed history taking and clinical examination, and if necessary, by appropriate radiological investigations. Evidence on the association between plaque-type psoriasis and cardiovascular disease risk factors and ischemic heart disease isinconsistent.On the basis ofavailable evidence, it is prudent to proactively look for metabolic syndrome, dyslipidemia, and obesity, especially in patientswith severe psoriasis (Level 1+ evidence based on systematic reviews and meta-analysis). Based on the current evidence, the psoriasis area severity index appears to be the most valid and reproducible clinical severity score in the management of adult patients with plaque-type psoriasis.

1 July 2013 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
AKAmrinder J. Kanwar
Amrinder J. Kanwar
RMRahul Mahajan
Rahul Mahajan
DPDavinder Parsad
Davinder Parsad
Background: The course of vitiligo is unpredictable. If the disease is spreading rapidly, the progression can be controlled with the use of systemic steroids daily or in pulsed form. The present study was planned to assess the efficacy of low-dose dexamethasone oral mini-pulse therapy in progressive unstable vitiligo. Materials and Methods: In this retrospective study, the case records of patients with vitiligo during the period from January 2006 to December 2010 were studied. Patients who had progressive unstable disease were included. These patients were administered oral dexamethasone 2.5 mg per day on 2 consecutive days after breakfast in a week. The patients were asked to come for regular follow-up to assess the arrest of disease activity, relapse of disease activity, and adverse effects. Results: A total of 444 patients were analyzed. In 408 (91.8%) patients, arrest of disease activity was achieved at a mean duration of 13.2 ± 3.1 weeks. In addition, some repigmentation of the lesions was seen in all patients after a mean of 16.1 ± 5.9 weeks. During the follow-up, 50 of 408 (12.25%) patients experienced one or two episodes of relapse in disease activity, which were treated with reinstitution of low-dose dexamethasone oral mini-pulse therapy. The mean disease-free survival (DFS) until the first relapse was 55.7 ± 26.7 weeks, and the mean DFS until the second relapse was 43.8 ± 7.2 weeks. Adverse reactions such as weight gain, lethargy, and acneiform eruptions were observed in 41 (9.2%) patients. Conclusion: Low-dose oral mini-pulse dexamethasone therapy is a good option for arresting progressive unstable vitiligo with minimal adverse effects.

10 July 2013 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SDSunil Dogra
Sunil Dogra
RMR. Mahajan
R. Mahajan

1 July 2016 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
RKRajiv Kumar
Rajiv Kumar
SDSunil Dogra
Sunil Dogra
BABasant Amarji
Basant Amarji
BSBhupinder Singh
Bhupinder Singh
SKSuresh Kumar
Suresh Kumar
OKOP Katare
OP Katare
The pathogenic role of T-cell–derived cytokines in psoriasis has led to considerable interest in exploring T-cell–specific calcineurin inhibitors in its treatment.1,2 Cyclosporine is approved by the US Food and Drug Administration (FDA) to treat recalcitrant chronic plaque psoriasis in nonimmunosuppressed patients at an oral dose of 2.5 to 5.0 mg/kg/d.3 Several attempts to use topical cyclosporine in varying dose regimens (0.1%-10% weight by weight [w/w]), in different topical vehicles, have failed to yield expected clinical response in treatment of various inflammatory dermatoses, including psoriasis.4-10 This has been attributed to the poor topical absorption resulting from the unfavorable physicochemical properties of the drug, such as poor aqueous solubility, large molecular weight, and high lipophilicity.9,11,12